{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T08:56:22Z","timestamp":1772787382901,"version":"3.50.1"},"reference-count":46,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2023,7,2]],"date-time":"2023-07-02T00:00:00Z","timestamp":1688256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Key R&amp;D Program of China","award":["2022YFC2304202"],"award-info":[{"award-number":["2022YFC2304202"]}]},{"name":"National Key R&amp;D Program of China","award":["31970873"],"award-info":[{"award-number":["31970873"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2022YFC2304202"],"award-info":[{"award-number":["2022YFC2304202"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31970873"],"award-info":[{"award-number":["31970873"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Antibody\u2014drug conjugates (ADCs) play important roles in tumor therapy. However, traditional ADCs are limited by the extremely large molecular weight of the antibody molecules, which results in low permeability into solid tumors. The use of small ADCs may be expected to alleviate this problem, but this switch brings the new limitation of a greatly shortened blood circulation half-life. Here, we propose a new cleavable ADC design with excellent tumor tissue permeability and a long circulation half-life by fusing the small ADC ZHER2-MMAE with the Fc domain of the antibody for circulation half-life extension, and inserting a digestion sequence between them to release the small ADC inside tumors for better tumor penetration. The experimental results showed that the designed molecule Fc-U-ZHER2-MMAE has a significantly increased blood circulation half-life (7.1 h, 59-fold longer) compared to the small ADC ZHER2-MMAE, and significantly improved drug accumulation ability at tumor sites compared to the conventional full-length antibody-coupled ADC Herceptin-MMAE. These combined effects led to Fc-U-ZHER2-MMAE having significantly enhanced tumor treatment ability, as shown in mouse models of NCI-N87 gastric cancer and SK-OV-3 ovarian cancer, where Fc-U-ZHER2-MMAE treatment achieved complete regression of tumors in all or a portion of animals with no obvious side effects and an MTD exceeding 90 mg\/kg. These data demonstrate the therapeutic advantages of this cleavable ADC strategy, which could provide a new approach for ADC design.<\/jats:p>","DOI":"10.3390\/ijms241311011","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:34:08Z","timestamp":1688344448000},"page":"11011","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Tumor Site-Specific Cleavage Improves the Antitumor Efficacy of Antibody\u2013Drug Conjugates"],"prefix":"10.3390","volume":"24","author":[{"given":"Keyuan","family":"Xu","sequence":"first","affiliation":[{"name":"State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, Nankai University, Tianjin 300071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiani","family":"Han","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, Nankai University, Tianjin 300071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu","family":"Yang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, Nankai University, Tianjin 300071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Cao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, Nankai University, Tianjin 300071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, Nankai University, Tianjin 300071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0086-4541","authenticated-orcid":false,"given":"Zhangyong","family":"Hong","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, Nankai University, Tianjin 300071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody-drug conjugates: A comprehensive review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nbt.2289","article-title":"The discovery and development of brentuximab vedotin for use in relapsed hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"30","author":"Senter","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"847835","DOI":"10.3389\/fmolb.2022.847835","article-title":"Antibody-drug conjugates targeting the human epidermal growth factor receptor family in cancers","volume":"9","author":"Yu","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"ref_4","first-page":"3183","article-title":"Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms","volume":"46","author":"Epenetos","year":"1986","journal-title":"Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"980","DOI":"10.4161\/cbt.6.6.4197","article-title":"In vitro efficacy of immuno-chemotherapy with anti-EGFR human fab-taxol conjugate on A431 epidermoid carcinoma cells","volume":"6","author":"Wang","year":"2007","journal-title":"Cancer Biol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Chen, X., Ding, G., Gao, Q., Sun, J., Zhang, Q., Du, L., Qiu, Z., Wang, C., Zheng, F., and Sun, B. (2013). A human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinoma. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0063093"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.intimp.2013.11.002","article-title":"Anti-hepatoma human single-chain Fv antibody and adriamycin conjugates with potent antitumor activity","volume":"18","author":"Chen","year":"2014","journal-title":"Int. Immunopharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: Natural single-domain antibodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annu. Rev. Biochem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1146\/annurev-pharmtox-010611-134654","article-title":"Designed ankyrin repeat proteins (darpins): Binding proteins for research, diagnostics, and therapy","volume":"55","year":"2015","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1021\/bc4004102","article-title":"Orthogonal assembly of a designed ankyrin repeat protein-cytotoxin conjugate with a clickable serum albumin module for half-life extension","volume":"24","author":"Simon","year":"2013","journal-title":"Bioconjugate Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/1568009617666170427105417","article-title":"Specific targeting of HER2-positive head and neck squamous cell carcinoma line hn5 by idarubicin-ZHER2 affibody conjugate","volume":"19","author":"Ghanemi","year":"2019","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/CJI.0000000000000125","article-title":"A novel affibody-auristatin e conjugate with a potent and selective activity against HER2+ cell lines","volume":"39","author":"Otlewski","year":"2016","journal-title":"J. Immunother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40259-015-0133-6","article-title":"Fusion proteins for half-life extension of biologics as a strategy to make biobetters","volume":"29","author":"Strohl","year":"2015","journal-title":"BioDrugs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nbt.1601","article-title":"Enhanced antibody half-life improves in vivo activity","volume":"28","author":"Zalevsky","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/emmm.201201379","article-title":"Fc-fusion proteins: New developments and future perspectives","volume":"4","author":"Czajkowsky","year":"2012","journal-title":"EMBO Mol. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jconrel.2019.02.016","article-title":"Current strategies in extending half-lives of therapeutic proteins","volume":"301","author":"Zaman","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"Fcrn: The neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cbpa.2016.08.006","article-title":"How pegylation influences protein conformational stability","volume":"34","author":"Lawrence","year":"2016","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1517\/14712598.2016.1165661","article-title":"Half-life extended biotherapeutics","volume":"16","author":"Kontermann","year":"2016","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.2174\/1381612825666190206105232","article-title":"Recent advances in half-life extension strategies for therapeutic peptides and proteins","volume":"24","author":"Tan","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12934-016-0601-9","article-title":"Elimination of n-glycosylation by site mutation further prolongs the half-life of InF-\u03b1\/Fc fusion proteins expressed in pichia pastoris","volume":"15","author":"Jia","year":"2016","journal-title":"Microb. Cell Factories"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2174\/156800909787314002","article-title":"The urokinase plasminogen activator system: A target for anti-cancer therapy","volume":"9","author":"Ulisse","year":"2009","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2147\/PPA.S235430","article-title":"Analysis of patient preferences in lung cancer\u2014Estimating acceptable tradeoffs between treatment benefit and side effects","volume":"14","author":"Janssen","year":"2020","journal-title":"Patient Prefer Adherence"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Tincknell, G., Piper, A.-K., Aghmesheh, M., Becker, T., Vine, K.L., Brungs, D., and Ranson, M. (2021). Experimental and clinical evidence supports the use of urokinase plasminogen activation system components as clinically relevant biomarkers in gastroesophageal adenocarcinoma. Cancers, 13.","DOI":"10.3390\/cancers13164097"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12929-020-00652-z","article-title":"Ab locks for improving the selectivity and safety of antibody drugs","volume":"27","author":"Lin","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00001813-200106000-00001","article-title":"The urokinase plasminogen activator receptor (upar) as a target for the diagnosis and therapy of cancer","volume":"12","author":"Mazar","year":"2001","journal-title":"Anticancer Drugs"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1158\/0008-5472.CAN-05-3521","article-title":"Tumor imaging using a picomolar affinity HER2 binding affibody molecule","volume":"66","author":"Orlova","year":"2006","journal-title":"Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nbt0897-772","article-title":"Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain","volume":"15","author":"Nord","year":"1997","journal-title":"Nat. Biotechnol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/protein\/1.2.107","article-title":"A synthetic igg-binding domain based on staphylococcal protein a","volume":"1","author":"Nilsson","year":"1987","journal-title":"Protein Eng."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.tibtech.2017.04.007","article-title":"Affibody molecules in biotechnological and medical applications","volume":"35","author":"Frejd","year":"2017","journal-title":"Trends Biotechnol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1021\/mp500762u","article-title":"Recent advances in the development of new auristatins: Structural modifications and application in antibody drug conjugates","volume":"12","author":"Maderna","year":"2015","journal-title":"Mol. Pharm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"12724","DOI":"10.1021\/acs.analchem.9b02192","article-title":"Comparison of analytical methods for antibody-drug conjugates produced by chemical site-specific conjugation: First-generation ajicap","volume":"91","author":"Matsuda","year":"2019","journal-title":"Anal. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nbt.1480","article-title":"Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index","volume":"26","author":"Junutula","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","article-title":"Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate","volume":"10","author":"Hamblett","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1021\/ja039915e","article-title":"Sortase-mediated protein ligation: A new method for protein engineering","volume":"126","author":"Mao","year":"2004","journal-title":"J. Am. Chem. Soc."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ejca.2006.01.004","article-title":"Inflammation, proteases and cancer","volume":"42","author":"Coussens","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"7583","DOI":"10.1073\/pnas.0511108103","article-title":"Protease specificity determination by using cellular libraries of peptide substrates (clips)","volume":"103","author":"Boulware","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"207ra144","DOI":"10.1126\/scitranslmed.3006682","article-title":"Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index","volume":"5","author":"Desnoyers","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1038\/nprot.2013.101","article-title":"Site-specific C-terminal and internal loop labeling of proteins using sortase-mediated reactions","volume":"8","author":"Guimaraes","year":"2013","journal-title":"Nat. Protoc."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"15039","DOI":"10.1073\/pnas.1005025107","article-title":"Structural basis for high-affinity HER2 receptor binding by an engineered protein","volume":"107","author":"Eigenbrot","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.2967\/jnumed.121.262123","article-title":"Affibody-mediated pna-based pretargeted cotreatment improves survival of trastuzumab-treated mice bearing her2-expressing xenografts","volume":"63","author":"Oroujeni","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ijpharm.2016.07.046","article-title":"Fusion of an albumin-binding domain extends the half-life of immunotoxins","volume":"511","author":"Guo","year":"2016","journal-title":"Int. J. Pharm."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2967\/jnumed.109.073346","article-title":"Targeting of HER2-expressing tumors using 111in-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold","volume":"51","author":"Ahlgren","year":"2010","journal-title":"J. Nucl. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00018-014-1751-8","article-title":"A new prodrug form of affibody molecules (pro-affibody) is selectively activated by cancer-associated proteases","volume":"72","author":"Jonsson","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1158\/1535-7163.MCT-19-1004","article-title":"Arx788, a site-specific anti-HER2 antibody-drug conjugate, demonstrates potent and selective activity in HER2-low and t-dm1-resistant breast and gastric cancers","volume":"19","author":"Skidmore","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_46","first-page":"175","article-title":"Preclinical evaluation of MRG002, a novel HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid tumors","volume":"4","author":"Li","year":"2021","journal-title":"Antib. Ther."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/13\/11011\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:04:51Z","timestamp":1760126691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/13\/11011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,2]]},"references-count":46,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["ijms241311011"],"URL":"https:\/\/doi.org\/10.3390\/ijms241311011","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,2]]}}}